WebNov 16, 2024 · The beta-amyloid theory in Alzheimer’s disease took another hit Monday when Roche announced that gantenerumab failed to meet the primary endpoint in two Phase III studies. The biopharma industry has spent the past two days responding in various ways. Several of Roche’s competitors, including Biogen, Cassava Sciences and Eli Lilly … WebNov 14, 2024 · “Any large scale clinical trial of an Alzheimer’s drug that fails is a massive disappointment to patients,” said Prof Jonathan Schott, a neurologist at UCL’s Dementia …

Roche Alzheimer’s Drug Fails Long-Running Trial

WebNov 14, 2024 · Nov 14 (Reuters) - Roche's (ROG.S) Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen (BIIB.O) and Eisai (4523.T) as... WebSep 23, 2024 · AC Immune, based in Lausanne, Switzerland, and Genentech, a U.S.-based Roche company, announced topline results from the TAURIEL Phase II clinical trial of semorinemab in early Alzheimer’s disease. The drug failed to meet its primary efficacy endpoint, as well as two secondary endpoints. Semorinemab is an anti-tau antibody. is there always pain with diverticulitis

Roche’s Alzheimer’s drug fails to meet goal in long awaited trial

WebJun 16, 2024 · A second late-stage study kicked off the next year. Negative results, though, led Roche to terminate both trials in 2024. The Colombian trial has since become somewhat of a last chance at proving crenezumab’s merit as an Alzheimer’s treatment. Thursday’s readout, then, puts the drug’s future in doubt. Roche said analyses are ongoing ... WebNov 14, 2024 · Ludwig Burger. (Reuters) -Roche's Alzheimer's drug candidate could not be shown to slow dementia progression in two drug trials, leaving rivals Biogen and Eisai as leaders in a high-stakes race to launch a treatment for the memory-robbing disease. Roche said in a statement on Monday that twin studies known as Graduate 1 and 2 had not … iht downsizing addition